By Chelsea Naso ( January 30, 2017, 7:41 PM EST) -- An ARIAD Pharmaceuticals shareholder launched a putative class action in Massachusetts federal court on Saturday over the hedge fund-backed oncology biotech's planned $5.2 billion sale to Japan's Takeda, alleging that the deal is the result of a conflicted sales process and lacks essential disclosures....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.